MX372705B - Composición farmacéutica que contiene budesonida y formoterol - Google Patents
Composición farmacéutica que contiene budesonida y formoterolInfo
- Publication number
- MX372705B MX372705B MX2017004583A MX2017004583A MX372705B MX 372705 B MX372705 B MX 372705B MX 2017004583 A MX2017004583 A MX 2017004583A MX 2017004583 A MX2017004583 A MX 2017004583A MX 372705 B MX372705 B MX 372705B
- Authority
- MX
- Mexico
- Prior art keywords
- powder
- weight
- amount
- lactose
- formoterol
- Prior art date
Links
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 title abstract 2
- 229960004436 budesonide Drugs 0.000 title abstract 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002848 formoterol Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000843 powder Substances 0.000 abstract 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 5
- 239000008101 lactose Substances 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000010419 fine particle Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion se refiere a formulaciones para inhalacion de farmacos en forma de polvo seco para administracion por inhalación,adecuadas para el tratamiento de enfermedades obstructivas de las vías respiratorias, tales como asma y enfermedad pulmonar obstructiva cronica (EPOC). En particular, la invencion se refiere a una composicion farmaceutica para inhalacion que comprende un primer polvo que comprende budesonida o una sal farmaceuticamente aceptable de la misma, en una cantidad mayor a 5% en peso de dicho primer polvo, leucina en una cantidad de 5 al 70% en peso de dicho primer polvo, lactosa en una cantidad de 20 a 90% en peso de dicho primer polvo; un segundo polvo que comprende formoterol o una sal farmaceuticamente aceptable del mismo, en una cantidad superior a 1% en peso de dicho segundo polvo, leucina en una cantidad de 5 a 70% en peso de dicho segundo polvo, lactosa en una cantidad de 20 a 90% en peso de dicho segundo polvo y un tercer polvo que comprende una mezcla de una primera lactosa que tiene un X50 de 35 a 75 um, con una segunda lactosa que tiene un X50 de 1.5 a 10 um, el contenido de dicha primera y segunda lactosa en dicha mezcla es, respectivamente, de 85% a 96% y de 4% a 15%. Dicha composicion tiene una fraccion de particulas finas (FPF) mayor al 60% y una fraccion suministrada (DF) mayor al 80%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI20141762 | 2014-10-08 | ||
| PCT/EP2015/073190 WO2016055546A1 (en) | 2014-10-08 | 2015-10-07 | Pharmaceutical composition containing budesonide and formoterol. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017004583A MX2017004583A (es) | 2017-11-20 |
| MX372705B true MX372705B (es) | 2025-03-05 |
Family
ID=51904068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017004583A MX372705B (es) | 2014-10-08 | 2015-10-07 | Composición farmacéutica que contiene budesonida y formoterol |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10449147B2 (es) |
| EP (1) | EP3203984B1 (es) |
| JP (1) | JP6684275B2 (es) |
| KR (1) | KR102449403B1 (es) |
| CN (2) | CN115844860A (es) |
| AU (2) | AU2015330012A1 (es) |
| CA (1) | CA2963445C (es) |
| CO (1) | CO2017004512A2 (es) |
| EA (1) | EA035755B1 (es) |
| ES (1) | ES2971768T3 (es) |
| IL (1) | IL251478B (es) |
| MX (1) | MX372705B (es) |
| MY (1) | MY191295A (es) |
| WO (1) | WO2016055546A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0613371B1 (en) * | 1991-12-18 | 2002-03-06 | AstraZeneca AB | New combination of formoterol and budesonide |
| GB9826783D0 (en) * | 1998-12-04 | 1999-01-27 | Scherer Ltd R P | Inhalation powders |
| GB9904919D0 (en) * | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| GB0009584D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
| EP1296651B2 (en) | 2000-06-27 | 2019-07-17 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
| US8337816B2 (en) * | 2001-09-17 | 2012-12-25 | Glaxo Group Limited | Dry powder medicament formulations |
| ITMI20051999A1 (it) | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| TR201000680A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler |
| WO2013109220A1 (en) * | 2012-01-16 | 2013-07-25 | Mahmut Bilgic | Dry powder formulations comprising tiotropium, formoterol and budesonide |
| US20150224197A1 (en) * | 2012-07-05 | 2015-08-13 | Arven Ilac Sanayi Ve Ticaret A.S. | Inhalation compositions |
| ITMI20130571A1 (it) * | 2013-04-10 | 2014-10-11 | Zambon Spa | Composizione farmaceutica contenente budesonide e formoterolo |
-
2015
- 2015-10-07 CA CA2963445A patent/CA2963445C/en active Active
- 2015-10-07 ES ES15784294T patent/ES2971768T3/es active Active
- 2015-10-07 KR KR1020177012308A patent/KR102449403B1/ko active Active
- 2015-10-07 WO PCT/EP2015/073190 patent/WO2016055546A1/en active Application Filing
- 2015-10-07 JP JP2017518998A patent/JP6684275B2/ja active Active
- 2015-10-07 MY MYPI2017701182A patent/MY191295A/en unknown
- 2015-10-07 EA EA201700183A patent/EA035755B1/ru unknown
- 2015-10-07 CN CN202211603766.XA patent/CN115844860A/zh active Pending
- 2015-10-07 AU AU2015330012A patent/AU2015330012A1/en not_active Abandoned
- 2015-10-07 CN CN201580066146.9A patent/CN107205958A/zh active Pending
- 2015-10-07 US US15/517,672 patent/US10449147B2/en active Active
- 2015-10-07 EP EP15784294.9A patent/EP3203984B1/en active Active
- 2015-10-07 MX MX2017004583A patent/MX372705B/es active IP Right Grant
-
2017
- 2017-03-30 IL IL251478A patent/IL251478B/en active IP Right Grant
- 2017-05-04 CO CONC2017/0004512A patent/CO2017004512A2/es unknown
-
2021
- 2021-01-21 AU AU2021200396A patent/AU2021200396B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CO2017004512A2 (es) | 2017-10-20 |
| EP3203984B1 (en) | 2024-01-17 |
| JP2017530987A (ja) | 2017-10-19 |
| CA2963445C (en) | 2023-07-18 |
| IL251478A0 (en) | 2017-05-29 |
| AU2015330012A1 (en) | 2017-05-25 |
| CN115844860A (zh) | 2023-03-28 |
| KR20170086489A (ko) | 2017-07-26 |
| MY191295A (en) | 2022-06-14 |
| MX2017004583A (es) | 2017-11-20 |
| IL251478B (en) | 2021-06-30 |
| BR112017007142A2 (pt) | 2017-12-19 |
| CN107205958A (zh) | 2017-09-26 |
| AU2021200396A1 (en) | 2021-03-18 |
| EA201700183A1 (ru) | 2017-10-31 |
| ES2971768T3 (es) | 2024-06-06 |
| US10449147B2 (en) | 2019-10-22 |
| WO2016055546A1 (en) | 2016-04-14 |
| KR102449403B1 (ko) | 2022-09-29 |
| US20170326067A1 (en) | 2017-11-16 |
| EP3203984A1 (en) | 2017-08-16 |
| EA035755B1 (ru) | 2020-08-05 |
| JP6684275B2 (ja) | 2020-04-22 |
| AU2021200396B2 (en) | 2023-02-09 |
| CA2963445A1 (en) | 2016-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| WO2013021199A3 (en) | Eutectic mixture for pulmonary administration | |
| BR112016022598A8 (pt) | composição aerossol farmacêutica na forma de um pó seco para liberação pulmonar, forma de dosagem unitária, pacote farmacêutico, kit e uso | |
| PH12015501882A1 (en) | Respirable agglomerates of porous carrier particles and micronized drug | |
| AR067639A1 (es) | Medicamentos pulverulentos que contienen tiotropio y salmetrol, asi como lactosa como excipiente | |
| EA201590030A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент | |
| WO2014016548A3 (en) | Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient | |
| PH12014502662A1 (en) | Novel dosage form and formulation of abediterol | |
| PE20141036A1 (es) | Nueva dosificacion y formulacion | |
| NZ627837A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| FI3500241T3 (fi) | Yhdistelmähoito copd:lle | |
| BR112015027017A2 (pt) | composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas | |
| EA201590019A1 (ru) | Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы | |
| EA201201397A1 (ru) | Ингалятор, содержащий расслаиваемую блистерную упаковку | |
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| MX373699B (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| MX2016001539A (es) | Particulas inhalables que comprenden tiotropio e indacaterol. | |
| UA115989C2 (uk) | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії | |
| MX372705B (es) | Composición farmacéutica que contiene budesonida y formoterol | |
| WO2019098969A3 (en) | Dry powder compositions for inhalation | |
| TR201620103A2 (tr) | İnhalasyon i̇le uygulanan formülasyonlar | |
| Kerwin et al. | B104 IT'S NO LONGER A SECRET SERVICE: UPDATES IN COPD PHARMACOTHERAPY: Efficacy And Safety Of Umeclidinium Added To Fluticasone Propionate/salmeterol In Patients With COPD: Results Of A Randomized, Double-Blind Study | |
| AR098868A1 (es) | Composición farmacéutica en polvo seco para inhalación | |
| TH1401007107A (th) | รูปฟอร์มขนาดใช้ยา และ สูตรผสมใหม่ของเอบีไดเทอรอล |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |